Jump to main content
Jump to site search

Issue 1, 2011
Previous Article Next Article

Development of LPS antagonistic therapeutics: synthesis and evaluation of glucopyranoside-spacer-amino acid motifs

Author affiliations

Abstract

Sepsis is a serious medical condition characterized by bacterial infection and a subsequent massive systemic inflammatory response. The release of proinflammatory products and mediators from responding innate immune cells, such as mononuclear phagocytes, directly contributes to the pathogenesis of sepsis. The primary bacterial trigger of inflammation is lipopolysaccharide (LPS), which interacts with the germline-encoded macrophage receptor cluster of differentiation 14 (CD14) via its Lipid A moiety. In an effort to identify compounds that block LPS-induced inflammation we investigated a series of Lipid A analogs that lack a disaccharide core yet still possess potent antagonistic activity against LPS. We found it beneficial to develop molecules that contain the following: a glucopyranoside core, hydrophobic ether substituents, and an amino acid to provide an ionic character to the constructs. Here we report an efficient synthesis of molecules of this type and the ensuing biological studies thereof.

Graphical abstract: Development of LPS antagonistic therapeutics: synthesis and evaluation of glucopyranoside-spacer-amino acid motifs

Back to tab navigation
Please wait while Download options loads

Supplementary files

Publication details

The article was received on 05 May 2011, accepted on 06 Jun 2011 and first published on 18 Jul 2011


Article type: Paper
DOI: 10.1039/C1RA00145K
Citation: RSC Adv., 2011,1, 83-92
  •   Request permissions

    Development of LPS antagonistic therapeutics: synthesis and evaluation of glucopyranoside-spacer-amino acid motifs

    S. Kaeothip, G. Paranjape, S. E. Terrill, A. F. G. Bongat, M. L. D. Udan, T. Kamkhachorn, H. L. Johnson, M. R. Nichols and A. V. Demchenko, RSC Adv., 2011, 1, 83
    DOI: 10.1039/C1RA00145K

Search articles by author